The effect of short-term proton pump inhibitor plus anti-ulcer drug on the healing of endoscopic submucosal dissection-derived artificial ulcer

A randomized controlled trial

Masakatsu Nakamura, Tomomitsu Tahara, Hisakazu Shiroeda, Kazuhiro Matsunaga, Toshimi Otsuka, Hoh Yonemura, Tomoyuki Shibata, Tomiyasu Arisawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aims: Artificial ulcers remain a major complication after Endoscopic submucosal dissection (ESD). The development of more effective treatment regimen for this ulcer is required than the use of proton pump inhibitor (PPI) alone. Methodology: Patients with ESD-derived artificial ulcers were randomly assigned to two groups: a group of patients who received rabeprazole 20 mg daily for 8 weeks (PPI group) and a group of patients who received a combination of rebamipide 300 mg daily for 8 weeks and rabeprazole 20mg dairy for the first 4 weeks (reb+PPI group). The area reduction ratio and healing status of ulcers were evaluated endoscopically on postoperative 7, 28 and 56 days. Results: The overall ulcer area reduction ratio was higher in the reb+PPI group than in the PPI group, especially at an early stage. The ratio of progression to the H1 stage in the reb+PPI group was significantly higher than that in the PPI group, especially at an early stage. Conclusions: Treatment with 8 weeks of rebamipide plus the first 4 weeks of PPI demonstrated a reduction ratio of artificial ulcers superior to that with 8 weeks of PPI mono-therapy. This combination treatment is, therefore, one of the candidate treatment strategies against ESD-derived artificial ulcers.

Original languageEnglish
Pages (from-to)219-224
Number of pages6
JournalHepato-Gastroenterology
Volume62
Issue number137
DOIs
Publication statusPublished - 01-01-2015

Fingerprint

Anti-Ulcer Agents
Proton Pump Inhibitors
Ulcer
Randomized Controlled Trials
Rabeprazole
Therapeutics
Endoscopic Mucosal Resection

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Nakamura, Masakatsu ; Tahara, Tomomitsu ; Shiroeda, Hisakazu ; Matsunaga, Kazuhiro ; Otsuka, Toshimi ; Yonemura, Hoh ; Shibata, Tomoyuki ; Arisawa, Tomiyasu. / The effect of short-term proton pump inhibitor plus anti-ulcer drug on the healing of endoscopic submucosal dissection-derived artificial ulcer : A randomized controlled trial. In: Hepato-Gastroenterology. 2015 ; Vol. 62, No. 137. pp. 219-224.
@article{1f382e57979440c2ab0db58e671c7fda,
title = "The effect of short-term proton pump inhibitor plus anti-ulcer drug on the healing of endoscopic submucosal dissection-derived artificial ulcer: A randomized controlled trial",
abstract = "Background/Aims: Artificial ulcers remain a major complication after Endoscopic submucosal dissection (ESD). The development of more effective treatment regimen for this ulcer is required than the use of proton pump inhibitor (PPI) alone. Methodology: Patients with ESD-derived artificial ulcers were randomly assigned to two groups: a group of patients who received rabeprazole 20 mg daily for 8 weeks (PPI group) and a group of patients who received a combination of rebamipide 300 mg daily for 8 weeks and rabeprazole 20mg dairy for the first 4 weeks (reb+PPI group). The area reduction ratio and healing status of ulcers were evaluated endoscopically on postoperative 7, 28 and 56 days. Results: The overall ulcer area reduction ratio was higher in the reb+PPI group than in the PPI group, especially at an early stage. The ratio of progression to the H1 stage in the reb+PPI group was significantly higher than that in the PPI group, especially at an early stage. Conclusions: Treatment with 8 weeks of rebamipide plus the first 4 weeks of PPI demonstrated a reduction ratio of artificial ulcers superior to that with 8 weeks of PPI mono-therapy. This combination treatment is, therefore, one of the candidate treatment strategies against ESD-derived artificial ulcers.",
author = "Masakatsu Nakamura and Tomomitsu Tahara and Hisakazu Shiroeda and Kazuhiro Matsunaga and Toshimi Otsuka and Hoh Yonemura and Tomoyuki Shibata and Tomiyasu Arisawa",
year = "2015",
month = "1",
day = "1",
doi = "10.5754/hge13631",
language = "English",
volume = "62",
pages = "219--224",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "137",

}

The effect of short-term proton pump inhibitor plus anti-ulcer drug on the healing of endoscopic submucosal dissection-derived artificial ulcer : A randomized controlled trial. / Nakamura, Masakatsu; Tahara, Tomomitsu; Shiroeda, Hisakazu; Matsunaga, Kazuhiro; Otsuka, Toshimi; Yonemura, Hoh; Shibata, Tomoyuki; Arisawa, Tomiyasu.

In: Hepato-Gastroenterology, Vol. 62, No. 137, 01.01.2015, p. 219-224.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of short-term proton pump inhibitor plus anti-ulcer drug on the healing of endoscopic submucosal dissection-derived artificial ulcer

T2 - A randomized controlled trial

AU - Nakamura, Masakatsu

AU - Tahara, Tomomitsu

AU - Shiroeda, Hisakazu

AU - Matsunaga, Kazuhiro

AU - Otsuka, Toshimi

AU - Yonemura, Hoh

AU - Shibata, Tomoyuki

AU - Arisawa, Tomiyasu

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background/Aims: Artificial ulcers remain a major complication after Endoscopic submucosal dissection (ESD). The development of more effective treatment regimen for this ulcer is required than the use of proton pump inhibitor (PPI) alone. Methodology: Patients with ESD-derived artificial ulcers were randomly assigned to two groups: a group of patients who received rabeprazole 20 mg daily for 8 weeks (PPI group) and a group of patients who received a combination of rebamipide 300 mg daily for 8 weeks and rabeprazole 20mg dairy for the first 4 weeks (reb+PPI group). The area reduction ratio and healing status of ulcers were evaluated endoscopically on postoperative 7, 28 and 56 days. Results: The overall ulcer area reduction ratio was higher in the reb+PPI group than in the PPI group, especially at an early stage. The ratio of progression to the H1 stage in the reb+PPI group was significantly higher than that in the PPI group, especially at an early stage. Conclusions: Treatment with 8 weeks of rebamipide plus the first 4 weeks of PPI demonstrated a reduction ratio of artificial ulcers superior to that with 8 weeks of PPI mono-therapy. This combination treatment is, therefore, one of the candidate treatment strategies against ESD-derived artificial ulcers.

AB - Background/Aims: Artificial ulcers remain a major complication after Endoscopic submucosal dissection (ESD). The development of more effective treatment regimen for this ulcer is required than the use of proton pump inhibitor (PPI) alone. Methodology: Patients with ESD-derived artificial ulcers were randomly assigned to two groups: a group of patients who received rabeprazole 20 mg daily for 8 weeks (PPI group) and a group of patients who received a combination of rebamipide 300 mg daily for 8 weeks and rabeprazole 20mg dairy for the first 4 weeks (reb+PPI group). The area reduction ratio and healing status of ulcers were evaluated endoscopically on postoperative 7, 28 and 56 days. Results: The overall ulcer area reduction ratio was higher in the reb+PPI group than in the PPI group, especially at an early stage. The ratio of progression to the H1 stage in the reb+PPI group was significantly higher than that in the PPI group, especially at an early stage. Conclusions: Treatment with 8 weeks of rebamipide plus the first 4 weeks of PPI demonstrated a reduction ratio of artificial ulcers superior to that with 8 weeks of PPI mono-therapy. This combination treatment is, therefore, one of the candidate treatment strategies against ESD-derived artificial ulcers.

UR - http://www.scopus.com/inward/record.url?scp=84928543588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928543588&partnerID=8YFLogxK

U2 - 10.5754/hge13631

DO - 10.5754/hge13631

M3 - Article

VL - 62

SP - 219

EP - 224

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 137

ER -